INSTRUCTIONS Annual drug update: 2010 in review
* To take the test online, go to our secure Web site at http://www.nursingcenter.com/ce/NP.
* On the print form, record your answers in the test answer section of the CE enrollment form on page 23. Each question has only one correct answer. You may make copies of these forms.
* Complete the registration information and course evaluation. Mail the completed form and registration fee of $29.95 to: Lippincott Williams & Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
* You will receive your CE certificate of earned contact hours and an answer key to review your results.There is no minimum passing grade.
* Registration deadline is February 28, 2013.
DISCOUNTS and CUSTOMER SERVICE
* Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together and deduct $0.95 from the price of each test.
* We also offer CE accounts for hospitals and other healthcare facilities on nursingcenter.com. Call 1-800-787-8985 for details.
Lippincott Williams & Wilkins, publisher of The Nurse Practitioner journal, will award 3.5 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 3.5 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454.
Your certificate is valid in all states. This activity has been assigned 3.5 pharmacology credits.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Annual drug update: 2010 in review
General Purpose: To familiarize the NP with recent FDA-approved drugs and their indications for use. Learning Objectives: After reading this article and taking this test, the NP will be able to: 1. Discuss indications for selected new drugs. 2. Identify adverse reactions, precautions, and dosing parameters for selected new drugs.
1. Tocilizumab (Actemra) is indicated for
a. patients with relapsing forms of multiple sclerosis.
b. patients 12 years and older with acne vulgaris.
c. patients with ankylosing spondylitis at risk for gastric ulcers.
d. adult patients with moderately to severely active RA who have had an inadequate response to one or more TNF antagonist therapies.
2. The recommended initial dose of tocilizumab, given every 4 weeks, is
a. 2 mg/kg.
b. 4 mg/kg.
c. 6 mg/kg.
d. 8 mg/kg.
3. Which test is required of patients before treatment with tocilizumab?
a. latent TB testing
b. cardiac stress test
c. creatinine clearance
d. prothrombin time
4. In patients who have an increased risk of CVD, rosuvastatin (Crestor) may now be used to reduce the risk of
b. type 2 diabetes.
d. pulmonary emboli.
5. Advise patients to take rosuvastatin
a. before meals.
b. after meals.
c. at the same time each day.
d. with food.
6. Which is a common adverse reaction to fingolimod (Gilenya)?
b. back pain
7. Patients taking fingolimod must be closely monitored for
c. increased lymphocyte count.
8. The recommended daily dosage of fingolimod is
a. 0.5 mcg.
b. 0.5 mg.
c. 0.5 mg/kg.
d. 5 mcg.
9. The mechanisms of action of dutasteride/tamsulosin (Jalyn) include
a. increasing smooth muscle tone in the bladder neck and prostate.
b. promoting conversion of testosterone to dihydrotestosterone.
c. inhibiting testosterone conversion and relaxing smooth muscle tone of the prostate.
d. decreasing urine flow.
10. Instruct patients to take dutasteride/tamsulosin once a day
a. 30 minutes before the same meal.
b. 30 minutes after the same meal.
c. upon arising.
d. at bedtime.
11. Prevnar 13 is approved for children ages
a. 4 weeks through 1 year.
b. 6 weeks through 5 years.
c. 2 months through 7 years.
d. 6 months through 12 years.
12. Before giving Prevnar 13, the prefilled syringe should be
a. rolled between the hands.
c. inverted once.
13. Which statement about olmesartan/amlodipine/hydrochlorothiazide (Tribenzor) is true?
a. It is used as initial therapy for treatment of hypertension.
b. It is a combination product that includes a beta-blocker.
c. It has no diuretic effect.
d. It has been shown to improve compliance over multiple drug therapy.
14. The maximum daily dose of Tribenzor is
a. 20/5/25 mg.
c. 40/10/25 mg.
b. 40/10/12.5 mg.
d. 60/20/50 mg.
15. Instruct patients using clindamycin phosphate/tretinoin gel (Veltin) to avoid
a. milk and dairy products.
c. sunlight and sunlamps.
16. Which patient may benefit from taking naproxen/esomeprazole magnesium (Vimovo)?
a. JJ, who has osteoarthritis
b. LW, who has hypertension
c. GB, who has acne vulgaris
d. TF, who has multiple sclerosis
17. The patient who should not be prescribed Vimovo is the one who
a. has a creatinine clearance of 60 to 80 mL/minute.
b. has hepatic failure.
c. is adverse to receiving injectable medications.
d. is taking antacids.
18. Instructions to patients taking Vimovo may state,
a. "take the medication 60 minutes before a meal."
b. "it is safe to use throughout pregnancy."
c. "divide the pill if it is too hard to swallow."
d. "do not take more than twice a day."
© 2011 Lippincott Williams & Wilkins, Inc.